PARP1 and melanoma: The cell death-inducing efficacy of PJ34 at higher concentrations than those inhibiting PARP activity has been also reported in a variety of breast cancer cell-lines, carrying or not BRCA mutations, and in a variety of triple-negative breast cancer cell-lines [46], as well as in melanoma cell lines and melanoma metastases [47], thyroid cancer cell lines [48], HeLa cells [49] and several glioblastoma cell lines [50].